Physician profile
Fakhre Alam
NPI 1427033828
$7,008.36
in general payments reported to CMS, 2019-2025
58 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $803 · 2021: $817 · 2022: $848 · 2023: $1,006 · 2024: $1,019 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,070 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,069.98 |
| Education | $206.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,010.13 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Teva Pharmaceuticals USA, INC. | $576.82 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $553.04 | 2019-2024 | |
| Pfizer INC. | $491.40 | 2021-2025 | |
| Ucb, INC. | $452.71 | 2019-2023 | Briviact |
| Acadia Pharmaceuticals INC | $412.69 | 2019-2025 | Nuplazid, Daybue |
| Eisai INC. | $367.61 | 2019-2025 | |
| Biogen, INC. | $269.64 | 2019-2025 | Vumerity |
| Genentech USA, INC. | $216.24 | 2019-2023 | Ocrevus |
| Amgen INC. | $186.22 | 2019-2024 | Uplizna |
| Sunovion Pharmaceuticals INC. | $183.60 | 2019-2022 | |
| Harmony Biosciences LLC | $177.60 | 2021-2025 | Wakix |
| Celgene Corporation | $162.37 | 2021-2025 | Zeposia |
| Allergan, INC. | $158.54 | 2020 | |
| Lilly USA, LLC | $155.72 | 2019-2024 | Emgality, Reyvow |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fakhre Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.